Acquired and hereditary forms of recurrent angioedema: Update of treatment
| Autor: | K. Bork |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Allergy
Bradykinin Review Article Pharmacology C1-inhibitor chemistry.chemical_compound medicine C1 esterase inhibitor deficiency heterocyclic compounds C1-INH concentrate Stanozolol General Environmental Science Danazol biology Angioedema business.industry angioedema General Engineering Oxandrolone medicine.disease bacterial infections and mycoses hereditary angioedema respiratory tract diseases chemistry bradykinin B2 receptor antagonist Hereditary angioedema biology.protein General Earth and Planetary Sciences Fresh frozen plasma medicine.symptom bradykinin business medicine.drug |
| Zdroj: | Allergologie Select |
| ISSN: | 2512-8957 |
| Popis: | The aim of treatment of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (HAE-C1-INH) is either treating acute attacks or preventing attacks by using prophylactic treatment. For treating acute attacks, plasma-derived C1 inhibitor (C1-INH) concentrates, a bradykinin B2 receptor antagonist, and a recombinant human C1-INH are available in Europe. In the United States, a plasma-derived C1-INH concentrate, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor were approved for the treatment of acute attacks. Fresh frozen plasma is also available for treating acute attacks. Short-term prophylactic treatment focuses on C1-INH and attenuated androgens. Long-term prophylactic treatments include attenuated androgens such as danazol, stanozolol, and oxandrolone, antifibrinolytics, and a plasma-derived C1-INH concentrate. Plasma-derived C1-INH and a bradykinin B2 receptor antagonist are admitted for self-administration and home therapy. So the number of management options increased considerably within the last few years thus helping to diminish the burden of HAE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|